Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials
Authors' conclusion
In both urate-lowering therapy and gout flare trials, there is substantial variability in when the core domains are measured, and reporting of collected measurements is inconsistent.
Study context
- Population
- Gout ULT and gout flare RCTs from 2005, identified from a prior systematic review of core domain reporting
- Participants
- 29 vs 14
- Comparison
- Urate-lowering therapy trials vs Gout flare trials
- Urate-lowering therapy trialsn = 29
- Gout flare trialsn = 14
- Outcome
- Time points and frequencies at which the OMERACT gout core domains are measured, and whether all collected measurements were reported
Pooled result
As reported in the abstract
- ULT trials: core domains measured at different frequencies
- 7
- ULT trials: all collected measurements reported, serum urate
- 24/29 (83%)
- ULT trials: all collected measurements reported, activity limitation
- 0/2 (0%)
- Gout flare trials: core domains measured at different frequencies
- 9
- Gout flare trials: all collected measurements reported, pain
- 13/14 (93%)
- Gout flare trials: all collected measurements reported, joint tenderness
- 3/8 (37.5%)
Original publication
Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials. Semin Arthritis Rheum. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →